Biotech stocks (IBB) that report disappointing clinical results follow the same pattern again and again. The stock sells off in a spectacular way. After a day or three, speculators buy the dip as volume drives up. The risk is obvious. For Novavax (NVAX), speculating on rebound might pay off.No technical chart would have predicted NVAX’s collapse, except for a descending channel that started last year in October. Novavax’s RSV (respiratory syncytial virus) failed its Phase 3 trial, which makes setting a target price impossible. On its annual investor meeting on October 11, the company must address what will happen next for its lead product. The stock is trading at around $2 a share and has $1.36 per share in cash. $AAPL, Apple Inc. / 60 Speculating on Novavax at this time may pay off ahead of this meeting. A clear response for addressing the weak clinical results will help the stock rebound. The $2.50 - $3.00 level is possible.